Peer-reviewed veterinary case report
Oral GS441524 works better than GC376 for feline infectious
By Yan, Yuanyuan et al.·Published in Veterinary microbiology·2023·College of Veterinary Medicine, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Better therapeutic effect of oral administration of GS441524 compared with GC376.
- Species:
- cat
Plain-English summary
A cat with feline infectious peritonitis (FIP), a serious viral disease, was treated with two different medications: GS441524 and GC376. The study found that GS441524 was more effective when given orally, significantly reducing the risk of death in affected cats, while GC376 only worked at higher doses. Both medications were shown to be absorbed well when taken by mouth, but GS441524 had the advantage of being absorbed more efficiently and lasting longer in the body. This research suggests that GS441524 could be a better option for treating FIP in cats.
People also search for: cat FIP treatment GS441524 · feline infectious peritonitis medication · GC376 for cats FIP
Abstract
FIP is a fatal feline disease caused by FIPV. Two drugs (GS441524 and GC376) target FIPV and have good therapeutic effect when administered by subcutaneous injection. However, subcutaneous injection has limitations compared with oral administration. Additionally, the oral efficacy of the two drugs has not been determined. Here, GS441524 and GC376 were shown to efficiently inhibit FIPV-rQS79 (recombination virus with a full-length field type I FIPV and the spike gene replaced with type II FIPV) and FIPV II (commercially available type II FIPV 79-1146) at a noncytotoxic concentration in CRFK cells. Moreover, the effective oral dose was determined via the in vivo pharmacokinetics of GS441524 and GC376. We conducted animal trials in three dosing groups and found that while GS441524 can effectively reducing the mortality of FIP subjects at a range of doses, GC376 only reducing the mortality rate at high doses. Additionally, compared with GC376, oral GS441524 has better absorption, slower clearance and a slower rate of metabolism. Furthermore, there was no significant difference between the oral and subcutaneous pharmacokinetic parameters. Collectively, our study is the first to evaluate the efficacy of oral GS441524 and GC376 using a relevant animal model. We also verified the reliability of oral GS441524 and the potential of oral GC376 as a reference for rational clinical drug use. Furthermore, the pharmacokinetic data provide insights into and potential directions for the optimization of these drugs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37269714/